194 related articles for article (PubMed ID: 20010939)
21. A subset of cancer cell lines is acutely sensitive to the Chk1 inhibitor MK-8776 as monotherapy due to CDK2 activation in S phase.
Sakurikar N; Thompson R; Montano R; Eastman A
Oncotarget; 2016 Jan; 7(2):1380-94. PubMed ID: 26595527
[TBL] [Abstract][Full Text] [Related]
22. Effects of structurally related flavonoids on cell cycle progression of human melanoma cells: regulation of cyclin-dependent kinases CDK2 and CDK1.
Casagrande F; Darbon JM
Biochem Pharmacol; 2001 May; 61(10):1205-15. PubMed ID: 11322924
[TBL] [Abstract][Full Text] [Related]
23. Resistance to cyclin-dependent kinase (CDK) 4/6 inhibitors confers cross-resistance to other CDK inhibitors but not to chemotherapeutic agents in breast cancer cells.
Ogata R; Kishino E; Saitoh W; Koike Y; Kurebayashi J
Breast Cancer; 2021 Jan; 28(1):206-215. PubMed ID: 32860163
[TBL] [Abstract][Full Text] [Related]
24. Estrogen and antiestrogen regulation of cell cycle progression in breast cancer cells.
Doisneau-Sixou SF; Sergio CM; Carroll JS; Hui R; Musgrove EA; Sutherland RL
Endocr Relat Cancer; 2003 Jun; 10(2):179-86. PubMed ID: 12790780
[TBL] [Abstract][Full Text] [Related]
25. Sensitivity of breast cancer cells to erlotinib depends on cyclin-dependent kinase 2 activity.
Yamasaki F; Zhang D; Bartholomeusz C; Sudo T; Hortobagyi GN; Kurisu K; Ueno NT
Mol Cancer Ther; 2007 Aug; 6(8):2168-77. PubMed ID: 17671085
[TBL] [Abstract][Full Text] [Related]
26. Differences in the Conformational Energy Landscape of CDK1 and CDK2 Suggest a Mechanism for Achieving Selective CDK Inhibition.
Wood DJ; Korolchuk S; Tatum NJ; Wang LZ; Endicott JA; Noble MEM; Martin MP
Cell Chem Biol; 2019 Jan; 26(1):121-130.e5. PubMed ID: 30472117
[TBL] [Abstract][Full Text] [Related]
27. Phosphorylation of mixed lineage kinase MLK3 by cyclin-dependent kinases CDK1 and CDK2 controls ovarian cancer cell division.
Cedeno-Rosario L; Honda D; Sunderland AM; Lewandowski MD; Taylor WR; Chadee DN
J Biol Chem; 2022 Aug; 298(8):102263. PubMed ID: 35843311
[TBL] [Abstract][Full Text] [Related]
28. Cyclin E-cdk2 activation is associated with cell cycle arrest and inhibition of DNA replication induced by the thymidylate synthase inhibitor Tomudex.
Yin MB; Guo B; Panadero A; Frank C; Wrzosek C; Slocum HK; Rustum YM
Exp Cell Res; 1999 Feb; 247(1):189-99. PubMed ID: 10047461
[TBL] [Abstract][Full Text] [Related]
29. KX-01, a novel Src kinase inhibitor directed toward the peptide substrate site, synergizes with tamoxifen in estrogen receptor α positive breast cancer.
Anbalagan M; Carrier L; Glodowski S; Hangauer D; Shan B; Rowan BG
Breast Cancer Res Treat; 2012 Apr; 132(2):391-409. PubMed ID: 21509526
[TBL] [Abstract][Full Text] [Related]
30. Inhibitors of Cyclin-Dependent Kinase 1/2 for Anticancer Treatment.
Mou J; Chen D; Deng Y
Med Chem; 2020; 16(3):307-325. PubMed ID: 31241436
[TBL] [Abstract][Full Text] [Related]
31. Nuclear targeting of cyclin-dependent kinase 2 reveals essential roles of cyclin-dependent kinase 2 localization and cyclin E in vitamin D-mediated growth inhibition.
Flores O; Wang Z; Knudsen KE; Burnstein KL
Endocrinology; 2010 Mar; 151(3):896-908. PubMed ID: 20147522
[TBL] [Abstract][Full Text] [Related]
32. Anti-HER2 antibody trastuzumab inhibits CDK2-mediated NPAT and histone H4 expression via the PI3K pathway.
Le XF; Bedrosian I; Mao W; Murray M; Lu Z; Keyomarsi K; Lee MH; Zhao J; Bast RC
Cell Cycle; 2006 Aug; 5(15):1654-61. PubMed ID: 16861913
[TBL] [Abstract][Full Text] [Related]
33. 6,7,4'-trihydroxyisoflavone inhibits HCT-116 human colon cancer cell proliferation by targeting CDK1 and CDK2.
Lee DE; Lee KW; Jung SK; Lee EJ; Hwang JA; Lim TG; Kim BY; Bode AM; Lee HJ; Dong Z
Carcinogenesis; 2011 Apr; 32(4):629-35. PubMed ID: 21258042
[TBL] [Abstract][Full Text] [Related]
34. Down-regulation of p21WAF1/CIP1 or p27Kip1 abrogates antiestrogen-mediated cell cycle arrest in human breast cancer cells.
Cariou S; Donovan JC; Flanagan WM; Milic A; Bhattacharya N; Slingerland JM
Proc Natl Acad Sci U S A; 2000 Aug; 97(16):9042-6. PubMed ID: 10908655
[TBL] [Abstract][Full Text] [Related]
35. BZL101, a phytochemical extract from the Scutellaria barbata plant, disrupts proliferation of human breast and prostate cancer cells through distinct mechanisms dependent on the cancer cell phenotype.
Marconett CN; Morgenstern TJ; San Roman AK; Sundar SN; Singhal AK; Firestone GL
Cancer Biol Ther; 2010 Aug; 10(4):397-405. PubMed ID: 20574166
[TBL] [Abstract][Full Text] [Related]
36. Dual Inhibition of CDK4 and CDK2 via Targeting p27 Tyrosine Phosphorylation Induces a Potent and Durable Response in Breast Cancer Cells.
Patel P; Tsiperson V; Gottesman SRS; Somma J; Blain SW
Mol Cancer Res; 2018 Mar; 16(3):361-377. PubMed ID: 29330290
[TBL] [Abstract][Full Text] [Related]
37. Silymarin and silibinin cause G1 and G2-M cell cycle arrest via distinct circuitries in human prostate cancer PC3 cells: a comparison of flavanone silibinin with flavanolignan mixture silymarin.
Deep G; Singh RP; Agarwal C; Kroll DJ; Agarwal R
Oncogene; 2006 Feb; 25(7):1053-69. PubMed ID: 16205633
[TBL] [Abstract][Full Text] [Related]
38. A pure estrogen antagonist inhibits cyclin E-Cdk2 activity in MCF-7 breast cancer cells and induces accumulation of p130-E2F4 complexes characteristic of quiescence.
Carroll JS; Prall OW; Musgrove EA; Sutherland RL
J Biol Chem; 2000 Dec; 275(49):38221-9. PubMed ID: 10991938
[TBL] [Abstract][Full Text] [Related]
39. Removal of Cdk inhibitors through both sequestration and downregulation in zearalenone-treated MCF-7 breast cancer cells.
Ahamed S; Foster JS; Bukovsky A; Diehl JA; Wimalasena J
Mol Carcinog; 2002 May; 34(1):45-58. PubMed ID: 12112322
[TBL] [Abstract][Full Text] [Related]
40. Estrogen receptor coregulator binding modulator (ERX-11) enhances the activity of CDK4/6 inhibitors against estrogen receptor-positive breast cancers.
Viswanadhapalli S; Ma S; Sareddy GR; Lee TK; Li M; Gilbreath C; Liu X; Luo Y; Pratap UP; Zhou M; Blatt EB; Kassees K; Arteaga C; Alluri P; Rao M; Weintraub ST; Tekmal RR; Ahn JM; Raj GV; Vadlamudi RK
Breast Cancer Res; 2019 Dec; 21(1):150. PubMed ID: 31878959
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
